{
  "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "docSlug": "9e6f9592721adb102aeba3d640e068ca",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 56,
  "pageCount": 64,
  "prevPage": 55,
  "nextPage": 57,
  "slideType": "key_takeaways",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes comparative size diagram of IMX-111 vs IgG antibody, bar chart of GLUT1 expression by tissue, box plot of GLUT1 expression by stage, and Kaplan-Meier survival curve.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/56",
  "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "deckJsonHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd.json",
  "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-56",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.5,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Percentage of tumors with increased GLUT1 expression compared to non-tumorous tissue",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b81aa0f9-8913-41fc-813d-e8618eb3e91e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.5,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Overexpression of GLUT1 Associated With Stage 3/4 Colorectal Cancer",
      "attrs": null,
      "subkind": "box",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66b34dc9-f152-4740-afd1-d566025d8b6b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.5,
        "y": 0.65
      },
      "kind": "chart",
      "text": "HCT-116 CRC Xenograft Model: Survival Curve",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad932cce-56a4-4611-bb08-a91223246454",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.02,
        "y": 0.35
      },
      "kind": "diagram",
      "text": "IMX-111 vs IgG Antibody size comparison",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c673091-f7f8-439c-92fd-a8916062040b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.15,
        "x": 0.35,
        "y": 0.18
      },
      "kind": "list",
      "text": "01: iMX-111's GLUT1 target is overexpressed on Colorectal and other cancers; 02: GLUT1 is associated with poor prognosis in colorectal cancer; 03: 100% survival @ 24 days vs. 0% control survival in colorectal cancer xenograft model",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f861d335-de35-4c66-919e-8af8358ee723",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.02,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "iMX-111 is a Tissue-Specific Biologic™ built on our TME Normalization™ Technology with proprietary GLUT1 antibody biomarker targeting facilitating preferential accumulation in glucose-consuming cancer cells such as colorectal cancer.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47277cf2-3146-4b50-a048-5621878e2c2c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Adapted from Abouzeid, et al. Anti-cancer activity of anti-GLUT1 antibody targeted polymeric micelles co-loaded with curcumin and doxorubicin (2013)...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "baca40a5-f605-46dc-b957-6a3a57627195",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "IMX-111: GLUT1 Biomarker-targeted for Colorectal Cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81e7f686-fee5-4dff-b636-090b8c8885bc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 64,
      "from": 37,
      "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}